Logo

PBM

Psyence Biomedical Ltd.

PBM

Psyence Biomedical Ltd. • NASDAQ
$1.55 ▼ -1.58% (-0.03)
Market Cap $1.11 M
52w High $62.96
52w Low $1.41
Dividend Yield 0%
P/E -0.02
Volume 98.76K
Outstanding Shares 713.23K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2024 $0 $1.157M ▲ $141.473K ▲ 0% $4.08 ▲ $146.204K ▲
Q3-2023 $0 $632.103K ▲ $-24.763M ▼ 0% $-1.85 ▼ $-632.101K ▼
Q2-2023 $0 $557.054K ▲ $-647.766K ▼ 0% $-0.084 ▼ $-557.05K ▼
Q1-2023 $0 $512.088K ▼ $-62.842K ▼ 0% $-0.008 ▼ $-512.09K ▲
Q4-2022 $0 $771.493K $-24.489K 0% $-0.002 $-771.49K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2024 $1.933M ▲ $2.253M ▲ $3.509M ▲ $-1.255M ▼
Q3-2023 $733.188 ▼ $1.132K ▼ $12.104K ▼ $-10.972K ▲
Q2-2023 $88.174K ▲ $12.681M ▼ $16.178M ▲ $-3.497M ▼
Q1-2023 $9.802K ▼ $16.726M ▲ $15.264M ▲ $1.461M ▼
Q4-2022 $15.956K $16.404M $14.88M $1.524M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2023 $-24.763K ▲ $-662 ▲ $0 ▼ $738.337 ▲ $73.197 ▼ $-665 ▲
Q2-2023 $-647.766K ▼ $-251.456K ▼ $4.21M ▲ $-3.88M ▼ $78.372K ▲ $-251.46K ▼
Q1-2023 $-62.842K ▼ $-251.425K ▲ $-247.5K ▼ $492.77K ▲ $-6.154K ▲ $-251.425K ▲
Q4-2022 $-24.489K ▼ $-550.221K ▼ $242.864M ▲ $-242.426M ▼ $-112.721K ▼ $-550.221K ▼
Q3-2022 $2.25M $-86.258K $0 $0 $-86.259K $-86.258K

Five-Year Company Overview

Income Statement

Income Statement Psyence Biomedical is still a pure development-stage biotech. It has essentially no operating revenue yet, and results are driven almost entirely by research and overhead costs. The company moved from small profits earlier on to a modest loss more recently, which is typical for a firm shifting into more serious clinical work. Overall, the income statement shows an early-stage business that has not yet proven commercial viability and remains dependent on external funding rather than internal cash generation.

Balance Sheet

Balance Sheet The balance sheet is very light, with only a small base of assets and no meaningful cash reported in the latest period. Equity has slipped into slightly negative territory, which suggests that accumulated losses have more than offset prior capital raised. There is a small amount of debt and limited asset backing, which together point to a fragile financial position and a likely need for additional financing as development progresses.

Cash Flow

Cash Flow Reported cash flow figures are essentially flat, which is more a sign of limited disclosed detail than of strong cash generation. In practice, a company at this stage is almost certainly consuming cash to fund trials and operations. With no operating revenue and no evident investment in physical assets, the main cash story is likely ongoing outflows for research and corporate expenses, offset by periodic capital raises. This implies sensitivity to market conditions and financing availability.

Competitive Edge

Competitive Edge Competitively, Psyence is trying to differentiate itself in three ways: using natural rather than synthetic psilocybin, focusing on the underserved palliative care market, and controlling its own cultivation and extraction through a licensed facility. This niche focus reduces direct head-to-head competition with larger psychedelic players that target mainstream depression. However, the company is still small, unproven clinically, and up against much better funded rivals, so its competitive position is promising in concept but untested in practice.

Innovation and R&D

Innovation and R&D Innovation is the clear strength here. Psyence is building around the idea that whole-mushroom extracts may work better than single-molecule drugs, supported by early preclinical indications of longer-lasting brain effects. Its lead candidate in palliative care is in mid-stage clinical testing, and the firm is also exploring longevity-related applications, which could open new markets if the science holds up. Partnerships with specialized research and manufacturing groups help extend its capabilities, but everything hinges on future trial results and regulatory responses, which remain uncertain.

Summary

Overall, Psyence Biomedical looks like a classic high-risk, early-stage biotech: rich in scientific ideas and differentiation, but very thin in revenue, assets, and balance sheet strength. The company’s unique focus on nature-derived psilocybin, palliative care, and longevity gives it a clear story and potential strategic moat, yet its financial profile signals reliance on continued external funding and successful clinical milestones. Future outcomes will depend heavily on clinical data, regulatory pathways, and the firm’s ability to secure stable, non-dilutive capital in a competitive and evolving psychedelic medicine landscape.

NEWS

November 25, 2025 · 7:00 AM UTC

Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program

Read more

November 24, 2025 · 10:58 AM UTC

Curaechoice Selects CVS Caremark at its PBM

Read more

November 20, 2025 · 7:00 AM UTC

Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets

Read more

November 12, 2025 · 7:00 AM UTC

Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs

Read more

November 6, 2025 · 7:00 AM UTC

Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care

Read more